He Yuxi, Zhang Yan, Liu Xin, Ghazaryan Emma, Li Ying, Xie Jianan, Su Guanfang
Department of Ophthalmology, Second Hospital, Jilin University, Ziqiang Street No. 218, Changchun 130041, Jilin, China.
Int J Mol Sci. 2014 Aug 20;15(8):14456-74. doi: 10.3390/ijms150814456.
Retinitis pigmentosa (RP) is a group of inherited retinal disorders characterized by progressive loss of photoreceptors and eventually leads to retina degeneration and atrophy. Until now, the exact pathogenesis and etiology of this disease has not been clear, and many approaches for RP therapies have been carried out in animals and in clinical trials. In recent years, stem cell transplantation-based attempts made some progress, especially the transplantation of bone marrow-derived mesenchymal stem cells (BMSCs). This review will provide an overview of stem cell-based treatment of RP and its main problems, to provide evidence for the safety and feasibility for further clinical treatment.
视网膜色素变性（RP）是一组遗传性视网膜疾病，其特征是光感受器逐渐丧失，最终导致视网膜变性和萎缩。到目前为止，这种疾病的确切发病机制和病因尚不清楚，并且已经在动物和临床试验中开展了许多针对RP的治疗方法。近年来，基于干细胞移植的尝试取得了一些进展，尤其是骨髓间充质干细胞（BMSC）的移植。本综述将概述基于干细胞治疗RP及其主要问题，为进一步临床治疗的安全性和可行性提供依据。
